real-time news and commentary for investors
Thursday, Aug 15
Seattle Genetics initiates Phase II trials for Adcetris to treat B-cell lymphoma
- Seattle Genetics (SGEN -2.2%) says it's initiated Phase II testing to evaluate Adcetris in combination with RCHOP, the current standard frontline therapy for newly diagnosed patients with diffuse large B-cell lymphoma.
- The primary endpoints of the study will assess the complete remission rate and safety profile of the drug combination.
- Secondary endpoints include objective response rate, progression-free survival and overall survival.